Japanese PAD patients under the microscope: rivaroxaban safety check
NCT ID NCT07142655
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study looked at the safety of the blood thinner rivaroxaban in 1500 Japanese patients with peripheral arterial disease (PAD) who had surgery to improve blood flow in their legs. Researchers used existing health records to track bleeding events and heart-related deaths. No new treatments or visits were required—only data from routine care were analyzed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE (PAD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Data Vision Co., Ltd
Tokyo, 101-0053, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple walk predict vascular disease? new study investigates
- New ultrasound technique aims to save limbs in artery disease patients
- Tailored blood thinners could save limbs in PAD patients
- Blood test may prevent clots after leg surgery
- Handball therapy: a playful path to better walking for seniors with leg artery disease
- New MRI contrast agent may improve artery blockage detection in legs